Prostate cancer is the second most common cancer in men worldwide. Although the aetiology of this disease remains largely unclear, several lines of evidence suggest that oxidative stress plays a role in prostate carcinogenesis. The antioxidant enzyme glutathione peroxidase 1 (GPX1) is part of the enzymatic antioxidant defence, preventing oxidative damage to DNA, proteins and lipids by detoxifying hydrogen and lipid peroxides that may contribute to prostate cancer development. Some studies indicate an association between GPX1 Pro198Leu polymorphism and an increased risk of cancer. The purpose of the present study was to determine the possible association of GPX1 Pro198Leu polymorphism and erythrocyte GPX activity with the risk of developing prostate cancer and to clarify whether erythrocyte GPX activity levels were correlated with the GPX1 Pro198Leu genotype in the Turkish population. The GPX1 Pro198Leu genotype was determined in 33 prostate cancer patients and 91 control individuals. As evident from our results, there was no difference between genotype and/or allele frequencies in prostate cancer patients and controls. No significant difference was found in GPX1 genotype or allele frequency between aggressive and non-aggressive prostate cancer patients. It can be suggested with these findings that individual susceptibility of prostate cancer may be modulated by GPX1 polymorphism, but it needs further studies.
Introduction
Prostate cancer continues to be a major age-related malignancy with most incidences occurring between 54 and 75 years and rapid onset after 45 years. Evidence from epidemiological, experimental and clinical studies suggests that prostate cancer cells are exposed to an increased oxidative stress. 1, 2 Reactive oxygen species (ROS), most notably the hydroxyl radicals, generated endogenously by cellular metabolism are known to cause oxidative DNA damage that has been implicated in prostate carcinogenesis. 3 The antioxidant enzyme glutathione peroxidase 1 (GPX1) is part of the enzymatic antioxidant defence, preventing oxidative damage to DNA, proteins and lipids by detoxifying hydrogen and lipid peroxides. 4, 5 The cytosolic form of GPX1 belongs to a family of selenium-dependent peroxidases that include cytosolic GPX, 6 plasma-based GPX3 7 and phospholipids hydroperoxidase GPX4. 8 GPX1 knockout mice have a normal phenotype but are highly sensitive to oxidative stressors. 9 Human GPX1 gene was found to possess several polymorphisms. The GPX1 gene has a GCG repeat polymorphism in exon 1, coding for a polyalanine tract of five to seven alanine residues. However, already there was a case-control study published by Kote-Jarai et al. 10 that showed no significant association between the GPX1 GCG repeat polymorphism and prostate cancer. On the other hand, GPX1 Pro198Leu is supposed to be functional. This polymorphism is associated with C to T substitution in the exon 2 of GPX1, which results in the amino acid change from proline (Pro) to leucine (Leu) at codon 198. 11 Studies that examine the possible association of the GPX1 Pro198Leu polymorphism with cancer have given contradictory results. Some studies reported that the Leu allele was associated with an increased risk of breast cancer, 4, 12 while others could not confirm these results. 13, 14 No association was found between the risk of basal cell carcinoma 15 and colorectal cancer. 16 However, most recent studies reported that the variant Leu allele was associated with a significant lower risk of lung cancer. 17, 18 The studies conducted on humans do not explicitly support the functional link between GPX1 genotype and GPX1 enzyme. 11 Ravn-Haren et al. 4 found that GPX1 activity was significantly lowered for the Leu allele compared to the Pro allele. However, this result is not consistent with one study, 19 suggesting no correlation between GPX1 activity and GPX1 genotype. Additionally, several factors have been observed to affect the activity of GPX1. Dietary intake of selenium increases GPX1 activity. Intake of fruit and vegetables, alcohol consumption and smoking may also influence the enzyme activity. 20 In the present study, we evaluated the possible association of the following three elements: GPX1 Pro198Leu polymorphism, erythrocyte GPX activity and prostate cancer.
Materials and methods Subjects
A total of 33 men diagnosed with primary, histologically confirmed prostate cancer (mean age: 67.52 + 9.31 years) and 91 controls (mean age: 64.57 + 8.72 years) were enrolled in the study. All patients were recruited from the outpatient clinic of the Urology Department of Gulhane Military Medical Academy, Turkey. Age-matched male subjects, who were admitted to the same hospital with histologically confirmed non-neoplastic diseases, served as controls. The study was approved by the Ethical Committee of Gulhane Military Medical Academy. Written informed consent was obtained from all participants of the study before collecting blood specimens. A questionnaire was used to elicit detailed information on demographic and clinical variables, smoking, prior disease history, and family history of cancer. None of the participants were taking antioxidant or vitamin supplements, including selenium, at the time of the study. None of the subjects had a drinking habit, and none of them had consumed any alcohol, starting at least 48 h prior to blood collection.
All tumours were diagnosed histologically with specimens obtained at biopsy or surgical resection by a senior pathologist at the Department of the Pathology. The cancerous tissue from prostate biopsies and prostatectomy specimens was graded according to the Gleason histopathological grading system, based on the architecture of the glandular tissue, glandular differentiation and cellular and nuclear appearance. 21 
Genotyping of GPX1 polymorphism
Blood samples were drawn from the antecubital vein, following an overnight fast, into tubes containing ethylenediaminetetraacetic acid (EDTA). Erythrocyte lysates were stored at À70 C until assayed, while genomic DNA was extracted from peripheral blood lymphocytes following standard proteinase K, phenol/chloroform extraction or ethanol precipitation procedure. 22 The GPX1 Pro198Leu polymorphism was genotyped by real-time polymerase chain reaction (PCR) as described by Ratnasinghe et al. 23 Briefly, oligonucleotide sequences for primers and probes to detect the C to T polymorphism in codon 198 were PCR forward TGTGCCCCTACGCAGGTACA, PCR reverse CCCCCGAGACAGCAGCA, C allele probe VIC CTGTCT CAAGGGCCCAGCTGTGC TAMRA and T allele probe FAM CTGTCTCAAGGGCTCAGCTGT GCCT TAMRA . Reactions (10 ml) contained approximately 20 ng genomic DNA isolated from whole blood, 2Â TaqMan Master Mix, dual-labelled probes (100 nM each) and PCR primers (900 nM each). The PCR reaction was run on a Mx3005P QPCR System (Stratagene, La. Jolla, CA, USA) under the following conditions: 50 C for 2 min, 95 C for 10 min, followed by 40 cycles of 95 C for 15 s and 62 C for 1 min. Genotyping was repeated on a random 10% samples and results were identical to the original run.
Erythrocyte GPX activity
GPX activity was measured in erythrocyte lysates as previously described by Eken et al. 24 Briefly, a reaction mixture containing 1 mmol/L Na 2 EDTA, 2 mmol/L reduced glutathione, 0.2 mmol/L NADPH, 4 mmol/L sodium azide and 1000 U glutathione reductase in 50 mmol/L TRIS buffer (pH 7.6) was prepared. A total of 20 ml of erythrocyte lysate and 980 ml of the reaction mixture were mixed and incubated for 5 min at 37 C. The reaction was initiated by adding 8.8 mmol/L hydrogen peroxide and the decrease of absorbance was recorded at 340 nm for 3 min. GPX activity is expressed in U/ml.
Statistical analysis
Demographic information stratified by case-control status was tabulated as a mean + standard deviation for continuous variables and a number (and percentage) for categorical variables. Pearson's w 2 test was used to assess group differences on categorical variables and a two-sample t test was used to assess group differences for continuous variables. Comparison of the erythrocyte GPX activity between cases and controls was carried out by a two-sample t test. A Kruskal-Wallis non-parametric analysis of variance (ANOVA) was used to assess whether mean concentration of erythrocyte GPX activities varied by genotype among the controls. Allele and genotype frequencies of cases and controls were compared with values predicted by Hardy-Weinberg equilibrium using the w 2 test. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated to evaluate the associations between GPX1 genotypes and prostate risk. Calculation for the case-control study was performed using the DeFinetti computer program, http:// ihg.gsf.de/cgi-bin/hw/hwa1.pl. In all cases, p values 0.05 were considered statistically significant. Additionally, study subjects were stratified according to age (based on age at diagnosis for cases or age at selection for controls) to evaluate the relationship of the GPX1 polymorphism with early-onset prostate cancer.
The association of the GPX1 polymorphism and disease status was studied with refitted models for non-aggressive and aggressive prostate cancer, respectively. Men diagnosed with high-grade cancer (Gleason score of 7-10) were categorized as having aggressive disease; those diagnosed with low-grade prostate cancer (Gleason score 2-6) were categorized as having non-aggressive disease.
For all analysis, we first examined the association of GPX1 Pro/Leu and Leu/Leu genotype, using Pro/ Pro genotype as a reference. Next, as a result of the lack of complete information on the functional significance of GPX1 Pro198Leu polymorphism, we analysed the data under the assumption of both dominant (grouping heterozygous with homozygous rare allele) and recessive models (grouping heterozygous with wild type). Table 1 shows a case-control comparison of selected baseline subject characteristics. As expected, free prostate specific antigen (PSA) levels were significantly different in cases compared with controls. Age and smoking status were not different in prostate cancer cases compared to controls.
Results

Subject characteristics
Erythrocyte GPX activity
As evident from the results shown in Table 2 , we found significantly lower erythrocyte GPX activity in the prostate cancer patients group versus controls (p < 0.001). Table 3 shows the association between GPX1 genotype and prostate cancer risk in Turkish study group. The genotype distribution of GPX1 Pro198Leu was in Hardy-Weinberg equilibrium among the controls. The frequencies of the variant Leu allele were 40.9% and 33.5% in cases and controls, respectively. Genotype frequencies were 33.3% (Pro/Pro), 51.5% (Pro/Leu) and 15.2% (Leu/Leu) for cases, and the respective frequencies were 44.0%, 45.1% and 11.0% for control individuals. As evident from our results, there was no difference between genotype and/or allele frequencies in prostate cancer cases and controls.
GPX1 polymorphism and prostate cancer risk
GPX1 polymorphism and age at diagnosis of prostate cancer
The relationship between the GPX1 polymorphism and prostate cancer risk among the cases and the controls stratified by age at diagnosis (for cases) and age at selection (for controls) is shown in 
GPX1 polymorphism, aggressive versus non-aggressive prostate cancer
No significant difference was found in GPX1 genotype or allele frequency between subgroups of cases divided by disease status (aggressive vs. nonaggressive prostate cancer; Table 5 ). Table 6 shows GPX1 genotype and corresponding GPX erythrocyte activity levels. When measured in erythrocytes, the GPX activity was not significantly different between the groups of individuals representing the Pro/Pro, Pro/Leu and Leu/Leu genetic variants, both in cases and in control subjects.
GPX1 genotype and GPX activity correlation
Discussion
In the present study, we found there was no difference between genotype and/or allele frequencies in prostate cancer cases and controls. Few studies have investigated the relationship of GPX1 Pro198Leu and prostate cancer risk. 2, 25 Choi et al. 25 failed to find associations between GPX1 Pro198Leu polymorphism and prostate cancer risk among men with a history of smoking and/or asbestos exposure. Further analyses stratified by factors related to environmental oxidative stress did not modify associations. 25 On the contrary, Arsova-Sarafinovska et al. 2 found an overall protective effect of the variant Leu allele of the GPX1 polymorphism on the prostate cancer risk. Furthermore, in our study we found lower erythrocyte GPX activity in the cancer group than in the healthy controls. These data confirmed our results obtained both in Macedonian and Turkish populations. It was also published in previous studies in which we reported that lower GPx activity was associated with prostate cancer. 2, 26 There are variable reports on the activity of this enzyme in prostate cancer. Jung et al. 27 found no differences in the antioxidant enzymatic activities of prostatic epithelial cell cultures between benign and malign tissue. In other studies, malignant epithelial cells in prostatic adenocarcinoma have been found to express lower levels of antioxidant enzymes than do benign prostatic epithelium 28 or almost no superoxide dismutase (SOD), GPX and catalase (CAT) enzyme. 29 With the lowered GPX activity in the cancer group, an accumulation of H 2 O 2 might occur, resulting in higher production of OH radicals. This highly reactive oxidant molecule binds and oxidizes DNA, lipids and proteins, and it reacts with structures in its close neighbourhood. Any oxidative lesion that is not repaired can lead to mutations, increasing the risk of carcinogenesis. 30 GPX is part of the defence system that neutralizes hydrogen peroxide. Heterozygous and homozygous carriers of the variant allele of the GPX1 Pro198Leu polymorphism are at 1.8-fold (95% CI, 1.2-2.8) and 2.3-fold (95% CI, 1.3-3.8) higher risk of lung cancer, respectively. 15 Homozygous carriers of the variant allele are at 1.9-fold (95% CI, 1.0-3.6) increased risk of breast cancer. 15 In this study, we determined the erythrocyte GPX activity in 33 cases and 91 controls and found no significant difference by genotype. Our results agree with previous studies that investigated the genotype-activity relationship of the GPX1 polymorphism and reported no difference in activity by genotype. 2, 19 Hansen et al. 20 also did not find any association between the GPX1 Pro198Leu polymorphism and colorectal cancer risk. On the contrary, the results of Ravn-Haren et al. 4 indicated that there were relationships between a well-known GPX1 polymorphism, erythrocyte GPX activity and breast cancer risk among postmenopausal women. They found that carriers of the variant T-allele of the GPX1 Pro198Leu polymorphism had a slightly higher risk of breast cancer compared with homozygous wildtype individuals. Our findings might seem somewhat contradictory: the effect of the GPX1 genotype on prostate cancer risk would be expected if GPX enzyme activity differs between the genotypes, such that a low-activity allele would be associated with a relatively high risk of prostate cancer due to less efficient prevention of oxidative damage to DNA caused by oxygen radicals. Thus, we must consider explanations other than the GPX enzyme activity.
Additionally, different dietary and lifestyle factors may influence GPX enzyme activity. In a recent human intervention study, it was shown that the intake of fruit and vegetables significantly increased the activity of GPX in human erythrocytes. 31 Several studies have shown selenium intake to be associated with GPX activity and gene expression 4 , particularly in populations with a low daily intake, less than 40 mg per day. 12, 20, 32 The actual dietary intake, alcohol consumption or smoking of that specific day may have influenced the GPX activity. 20 Alcohol induces lipid peroxidation and has been also reported to decrease erythrocyte GPX activity in some human studies but not in others. 4, 18 The complete story of the GPX1 genotype is probably complex, a situation that has proven true for many or most single-nucleotide polymorphisms.
Risk of prostate cancer increases with age, indicating that inflammatory processes and cumulative exposure to ROS over the life course could be related to carcinogenesis in the prostate. In this study, there was an association in the subgroup of men older than 65 years, whereas no significant association was found in the subgroup of younger men. Vogel et al. 15 also found that age at diagnosis of basal cell carcinoma did not modify the association between genotype and cancer risk. More studies are needed to draw a firm conclusion on the associations between the GPX1 Pro198Leu polymorphism, GPX activity and age in relation with cancer risk.
We also tested the associations stratified by disease status, but the GPX1 genotype was not associated with non-aggressive or aggressive prostate cancer. This is an agreement with results from other studies. 2, 25 In conclusion, prostate carcinoma in Turkish subjects is associated with alterations in systemic antioxidant activities, which may play an important role in carcinogenesis. These changes in GPX1 activity may break the balance between oxidative stress and antioxidant defences, and therefore influence the cancer risk. In this context our findings suggest that ROS may play an important role in prostate carcinogenesis, and individual susceptibility of prostate cancer may be modulated by GPX1 polymorphism. We expected that intake of antioxidants would be protective against prostate cancer risk particularly among individuals with a lowered defence against oxidative stress. Nonetheless, more functional studies of the GPX1 polymorphism in other oxidative stress response genes in large-pooled studies will help to clarify their role in prostate carcinogenesis. If confirmed by other studies, these findings could improve the assessment of prostate cancer risk and clinical management in these patients.
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